[go: up one dir, main page]

WO2021170113A1 - Méthode de traitement de coronavirus à l'aide d'une protéine de fusion ace-2-fc - Google Patents

Méthode de traitement de coronavirus à l'aide d'une protéine de fusion ace-2-fc Download PDF

Info

Publication number
WO2021170113A1
WO2021170113A1 PCT/CN2021/078270 CN2021078270W WO2021170113A1 WO 2021170113 A1 WO2021170113 A1 WO 2021170113A1 CN 2021078270 W CN2021078270 W CN 2021078270W WO 2021170113 A1 WO2021170113 A1 WO 2021170113A1
Authority
WO
WIPO (PCT)
Prior art keywords
region
protein
ace2
dimer
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/078270
Other languages
English (en)
Chinese (zh)
Inventor
汪伟明
曾明
张娴
武波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Nanjing Legend Biotechnology Co Ltd
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Nanjing Legend Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp, Nanjing Legend Biotechnology Co Ltd filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of WO2021170113A1 publication Critical patent/WO2021170113A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Definitions

  • the invention belongs to the field of virus therapy, and relates to a method and a pharmaceutical composition for treating SARS-CoV-2 and related coronaviruses caused by an ACE2-Fc fusion protein.
  • SARS-CoV-2 also known as SARS-CoV-2
  • SARS-CoV-2 has infected more than 67,000 people worldwide, and more than 1,000 people have died and have not been effectively controlled.
  • Our understanding of the SARS-CoV-2 virus transmission route and other transmission dynamics, clinical disease manifestations, and pathology (such as the length of the incubation period) is still very limited.
  • SARS-CoV severe acute respiratory syndrome
  • SARS-CoV-2 enters host cells through the combination of spike glycoprotein (S) and receptor angiotensin-converting enzyme 2 (ACE2).
  • S spike glycoprotein
  • ACE2 receptor angiotensin-converting enzyme 2
  • US 9,561,263 gene recombination technology
  • ACE2 As the receptor for SARS-CoV-2 to enter the cell, ACE2 exists as a dimer on the cell membrane and has two conformations: "open” and “closed". The conversion between the two conformations is achieved by the rotation of the protease domain (PD) on ACE2, and PD is the direct binding site of the coronavirus S protein, which is the entrance for the virus to infect the human body. It has been previously reported that ACE2 can form dimers (U.S. 8,586,319). However, the dimer formed by ACE-2 used as a drug to prevent SARS-CoV-2 virus from entering the host cell to prevent virus infection has not been verified and tried.
  • PD protease domain
  • the present invention provides a specific and effective recombinant fusion protein and a method for preventing or treating SARS-CoV-2 infection by using the protein.
  • the method of the present invention is effective against multiple virus strains of SARS-CoV-2 and other close relative strains of the coronavirus.
  • the invention can also be used to detect or diagnose SARS-CoV-2 and the diseases caused by it.
  • the present invention found that the ACE2 dimer can bind with SARS-CoV-2 S protein with high affinity, and its binding force is higher than that with SARS-CoV-2 S protein.
  • the present invention further discovered that the neutralizing ability of ACE-2 dimer for SARS-CoV-2 is 10 times that of SARS virus.
  • the present invention suggests that ACE-2 dimer is a novel therapeutic agent for SARS-CoV-2.
  • ACE2 can form a dimer by adding an Fc segment to the C-terminus, and bind to SARS and SARS-CoV-2 S proteins and have similar binding capabilities.
  • the present invention further found that even though the ACE-2-Fc binding ability is equivalent, the neutralizing ability of ACE-2-Fc to SARS-CoV-2 is 10 times that of SARS virus.
  • the present invention suggests that the dimer formed by ACE-2-Fc is a novel therapeutic agent for SARS-CoV-2.
  • One aspect of the present invention provides a recombinant fusion protein, including angiotensin converting enzyme 2 (ACE2) region and an immunoglobulin Fc region.
  • ACE2 region is connected to the Fc region of the immunoglobulin, and the fusion protein can bind to the spike protein of the coronavirus, thereby blocking the binding of ACE2 to the spike protein of the coronavirus.
  • the ACE2 region is the extracellular domain of ACE2.
  • the ACE2 region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the sequence shown in SEQ ID NO:1.
  • the ACE2 region sequence is shown in SEQ ID NO:1.
  • the Fc region of the immunoglobulin comprises the Fc region of IgG1, the Fc region of IgG4, or a mutant of the IgG4 Fc region.
  • the Fc region of the immunoglobulin comprises the Fc region of human IgG1.
  • the Fc region of the immunoglobulin comprises the Fc region of human IgG4 or a variant thereof.
  • the Fc region of the immunoglobulin comprises the Fc region of IgG2.
  • the Fc region of the immunoglobulin comprises the Fc region of murine IgG2.
  • the immunoglobulin Fc region is the Fc region of IgG1.
  • the Fc region of the immunoglobulin is the Fc region of IgG2.
  • the immunoglobulin Fc region is the Fc region of IgG4.
  • the ACE2 region is directly connected to the immunoglobulin Fc region or through an alternative linker.
  • the ACE2 region and the immunoglobulin Fc region are directly connected by forming an amide bond.
  • the ACE2 region and the immunoglobulin Fc region are connected by a linker.
  • the linker is a polypeptide linker, such as a GS linker.
  • the linker comprises the amino acid sequence shown in SEQ ID NO:6. In a specific embodiment, the amino acid sequence of the linker is shown in SEQ ID NO: 6.
  • the coronavirus is selected from SARS-CoV, MERS-CoV or SARS-CoV-2, preferably SARS-CoV-2.
  • the recombinant fusion protein comprises at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the sequence shown in SEQ ID NO: 2, 3 or 4.
  • sexual amino acid sequence In a specific embodiment, the recombinant fusion protein comprises the amino acid sequence shown in SEQ ID NO: 2, 3 or 4. In another specific embodiment, the recombinant fusion protein comprises the amino acid sequence shown in SEQ ID NO: 2 or 3. In a specific embodiment, the amino acid sequence of the recombinant fusion protein is shown in SEQ ID NO: 2, 3 or 4.
  • Another aspect of the present invention provides a dimer formed by the above-mentioned recombinant fusion protein.
  • Two recombinant fusion proteins forming the dimer are connected by any linker or automatically form a dimer.
  • Another aspect of the present invention provides a recombinant protein dimer, including any form of dimer formed by the ACE2 region.
  • a recombinant protein dimer including any form of dimer formed by the ACE2 region.
  • two of the ACE2 regions are joined by any linker to form or automatically form a dimer.
  • the linker is selected from polypeptides or disulfide bonds. In other embodiments, the linker is a chemical linker. In a specific embodiment, the linker comprises an immunoglobulin Fc region. In a specific embodiment, the ACE2 region is connected to the Fc region of an immunoglobulin to form a dimer through one or more disulfide bonds in the Fc region. In another specific embodiment, the ACE2 region is connected to the immunoglobulin Fc region by comprising the amino acid sequence shown in SEQ ID NO:6. In some embodiments, the Fc region of the immunoglobulin comprises the Fc region of IgG1, the Fc region of IgG2, the Fc region of IgG4, or a variant of the IgG4 Fc region.
  • the ACE2 region is the extracellular domain of ACE2.
  • the ACE2 region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the sequence shown in SEQ ID NO:1.
  • the ACE2 region sequence is shown in SEQ ID NO:1.
  • the present invention also provides a polynucleotide encoding the above-mentioned recombinant fusion protein or the dimer of the recombinant fusion protein or the dimer of the recombinant protein, further comprising an expression vector of the polynucleotide, and further comprising an expression vector of the expression vector Host cell.
  • Another aspect of the present invention provides a pharmaceutical composition, which comprises the above-mentioned recombinant fusion protein or the dimer of the above-mentioned recombinant fusion protein or the recombinant protein dimer, and a pharmaceutically acceptable carrier.
  • the present invention provides a method for preventing, treating or alleviating coronavirus infection, the method comprising administering the above-mentioned recombinant fusion protein, the dimer of the above-mentioned recombinant fusion protein, or the dimerization of the above-mentioned recombinant fusion protein to a subject who is infected or suspected of being infected with the coronavirus Body, or the above-mentioned pharmaceutical composition.
  • Another aspect of the present invention provides a method for detecting coronavirus in a sample, the method comprising: a. contacting the above-mentioned recombinant fusion protein, the above-mentioned recombinant fusion protein dimer or the recombinant protein dimer with the sample; b. It is determined whether the recombinant fusion protein or the dimer of the recombinant fusion protein or the recombinant protein dimer specifically binds to the molecules in the sample.
  • coronavirus is selected from SARS-CoV-2.
  • the sample of the present invention is derived from serum, whole blood, sputum, oral/nasopharyngeal secretions or lotions, urine, feces, pleural effusion, cerebrospinal fluid, tissues that are infected or suspected of being infected with SARS-CoV-2 virus Specimen or non-biological samples such as water, beverages.
  • the present invention also provides a method for preventing, treating or alleviating coronavirus infection, the method comprising administering a protein containing the extracellular domain of ACE2 to a subject infected or suspected of being infected with a coronavirus, and the coronavirus is SARS-CoV-2
  • the ACE2 extracellular domain includes the amino acid sequence shown in SEQ ID NO:1.
  • the amino acid sequence of the extracellular domain of ACE2 is shown in SEQ ID NO:1.
  • the present invention also provides the application of the protein containing the ACE2 extracellular domain in the preparation of drugs for preventing, treating or alleviating SARS-CoV-2 coronavirus infection, wherein the ACE2 extracellular domain comprises the amino acid sequence shown in SEQ ID NO:1.
  • the amino acid sequence of the extracellular domain of ACE2 is shown in SEQ ID NO:1.
  • the protein exists as a dimer.
  • SARS-CoV-2 also known as 2019-nCoV
  • 2019-nCoV belongs to the ⁇ -coronavirus, has an envelope, and the particles are round or elliptical, often pleomorphic, with a diameter of 60-140nm . Its genetic characteristics are obviously different from SARS-CoV and MERS-CoV. Studies have shown that it has more than 85% homology with bat SARS-like coronavirus (bat-SL-CoVZC45).
  • bat SARS-like coronavirus bat SARS-like coronavirus
  • SARS-CoV-2 can be found in human respiratory epithelial cells in about 96 hours, while it takes about 6 days to isolate and culture in Vero E6 and Huh-7 cell lines.
  • Fc region of immunoglobulins refers to the fragment crystallizable (Fc) of immunoglobulins, in which immunoglobulins are generally composed of two identical light chains and two identical heavy chains. Peptide chain structure connected by disulfide bonds. It also refers to antibodies, which can be divided into five categories, namely immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin D (IgD) and immunoglobulin E (IgE) , Is composed of two parts, the antigen-binding fragment Fab and the crystallizable fragment Fc, where Fab can bind to antigen and Fc can bind to Fc receptors.
  • IgG immunoglobulin G
  • IgA immunoglobulin A
  • IgM immunoglobulin M
  • IgD immunoglobulin D
  • IgE immunoglobulin E
  • the Fc region of an immunoglobulin may be IgG Fc, such as IgG1 Fc, IgG2 Fc, IgG4 Fc or variants thereof.
  • the Fc of IgG can be of human or murine origin.
  • the immunoglobulin Fc region may be the Fc of human IgG1, the Fc of human IgG4, or the Fc of murine IgG2.
  • the Fc region of the immunoglobulin may be the Fc of human IgG4 or a variant thereof.
  • the Fc of human IgG4 comprises the amino acid sequence shown in SEQ ID NO:7. Specifically, the amino acid sequence of the Fc region of human IgG4 is shown in SEQ ID NO:7.
  • a variant of the Fc region of human IgG4 refers to a sequence of the Fc region of human IgG4 that contains one or more amino acid substitutions, deletions or insertions. If the Fc region of human IgG4 contains substitutions at positions 228 and 235, the substitutions can be S228P and/or L235E.
  • the human IgG4Fc variant comprises the amino acid sequence shown in SEQ ID NO: 8 or 9. Specifically, the amino acid sequence of the human IgG4Fc variant is shown in SEQ ID NO: 8 or 9.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersants, coatings, antibacterial and antifungal agents, isotonic and sustained release agents, and the like that are compatible with drug administration. Suitable carriers are described in the standard reference documents in the latest edition of Remington’s Pharmaceutical Sciences, which are incorporated herein by reference in their entirety. Examples of suitable carriers or diluents include, but are not limited to, water, saline solution, ringer's solution, glucose solution, and 5% human serum albumin. Liposomes and hydrophobic-aqueous media such as fixed oils can also be used. The use of media and agents for pharmaceutically active substances is well known in the art. Except for those conventional media or reagents that are incompatible with the active ingredients, its use in the ingredients can achieve the desired effect.
  • the "percent (%) amino acid sequence identity" of a peptide or polypeptide sequence is defined as comparing the sequences and introducing gaps when necessary to obtain the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.
  • Candidates The percentage of amino acid residues in the sequence that are identical to the amino acid residues in the specific peptide or polypeptide sequence. Sequence comparisons can be performed in a variety of ways within the skill of the art to determine percent amino acid sequence identity, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for measuring the comparison, including any algorithm required to obtain the maximum comparison over the entire length of the sequence being compared.
  • administering and “treatment” are used to refer to animals, humans, experimental subjects, cells, tissues, organs, or biological fluids, it means to combine exogenous drugs, therapeutic agents, diagnostic agents or compositions with animals, humans, and recipients. Contact with the person being treated, cells, tissues, organs or biological fluids.
  • administering can refer to, for example, treatment methods, pharmacokinetic methods, diagnostic methods, research methods, and experimental methods. Treating cells includes contacting the reagent with the cell and contacting the reagent with a fluid, where the fluid is in contact with the cell.
  • administering and “treatment” also mean the treatment of cells in vitro and ex vivo, for example, by reagents, diagnostic agents, binding compositions, or by other cells.
  • subject refers to an animal in need of alleviation, prevention and/or treatment of a disease or condition such as a viral infection, preferably a mammal, more preferably a human.
  • a disease or condition such as a viral infection, preferably a mammal, more preferably a human.
  • the term includes human subjects who have a coronavirus such as SARS-CoV-2 infection or are at risk of having a coronavirus such as SARS-CoV-2 infection.
  • “Pharmaceutically acceptable carrier” refers to a carrier for administration, including various excipients, diluents and buffers, etc. These substances are suitable for human and/or animal administration without excessive adverse side effects, and at the same time It is suitable for maintaining the vitality of the drug or active agent located therein.
  • the recombinant fusion protein of the present invention includes two parts: angiotensin converting enzyme 2 (ACE2) region and immunoglobulin Fc region.
  • ACE2 angiotensin converting enzyme 2
  • the recombinant fusion protein includes an angiotensin-converting enzyme 2 (ACE2) region, which is connected to the Fc region of an immunoglobulin, and the fusion protein can bind to the spike protein of the coronavirus, thereby blocking ACE2 Binding with the coronavirus spike protein.
  • ACE2 region is the extracellular domain of ACE2.
  • the ACE2 region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the sequence shown in SEQ ID NO:1.
  • the ACE2 region sequence is shown in SEQ ID NO:1.
  • the present invention can use any Fc fragment of immunoglobulin.
  • Immunoglobulins include IgG, IgA, IgM, IgD and IgA, of which IgG is the most abundant and relatively stable.
  • the Fc fragment of IgG such as the Fc fragment of IgG1, the Fc fragment of IgG2, the Fc fragment of human IgG1 or the Fc fragment of mouse IgG2, is preferred, because these Fc fragments show the highest binding to staphylococcus protein A (staphylococcus Protein A) It is easy to be purified.
  • the Fc region of the immunoglobulin comprises the Fc region of IgG1. In some preferred embodiments, the Fc region of the immunoglobulin comprises the Fc region of human IgG1. In other embodiments, the Fc region of the immunoglobulin comprises the Fc region of IgG2. In some preferred embodiments, the Fc region of the immunoglobulin comprises the Fc region of murine IgG2a.
  • the recombinant fusion protein includes at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the sequence shown in SEQ ID NO: 2, 3 or 4.
  • Sexual amino acid sequence In some embodiments, the recombinant fusion protein includes at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the sequence shown in SEQ ID NO: 2 or 3.
  • Amino acid sequence includes the amino acid sequence shown in SEQ ID NO: 2, 3 or 4.
  • the recombinant fusion protein includes the amino acid sequence shown in SEQ ID NO: 2.
  • the recombinant fusion protein includes the amino acid sequence shown in SEQ ID NO: 3.
  • the recombinant fusion protein includes the amino acid sequence shown in SEQ ID NO:4.
  • Another aspect of the present invention provides a dimer formed by the above-mentioned recombinant fusion protein.
  • Two recombinant fusion proteins forming the dimer are connected by any linker or automatically form a dimer.
  • a homodimer of a recombinant fusion protein is provided, wherein the homodimer includes two fusion protein molecules connected by one or more disulfide bonds.
  • the length of the Fc fragment in the present invention can be 232 amino acids, including one cysteine in the hinge region, two cysteines in the CH2 region, and two cysteines in the CH3 region.
  • the cysteine in the hinge region is used to form a disulfide bond between the two monomers, thereby producing a dimer.
  • the cystine in the CH2 region and the CH3 region can form an intra-bond disulfide bond to stabilize the recombinant fusion A homodimer of protein.
  • Another aspect of the present invention provides a recombinant protein dimer, including any form of dimer formed by the ACE2 region.
  • two of the ACE2 regions are connected by any linker to form or automatically form a dimer.
  • the linker includes any chemical linker that can connect the ACE2 protein.
  • the linker is selected from polypeptides or disulfide bonds.
  • the linker is an immunoglobulin Fc region.
  • the present invention can use any Fc fragment of immunoglobulin.
  • Immunoglobulins include IgG, IgA, IgM, IgD and IgA, of which IgG is the most abundant and relatively stable.
  • the Fc fragment of IgG such as the Fc fragment of IgG1, the Fc fragment of IgG2, the Fc fragment of human IgG1 or the Fc fragment of mouse IgG2, is preferred, because these Fc fragments show the highest level of staphylococcus protein A (staphylococcus Protein A). It is easy to be purified because of its binding properties.
  • the present invention includes any ACE2 dimer, ACE2-linker-ACE2, or ACE-Fc that can automatically form a dimer after expression.
  • the recombinant protein dimer is that the ACE region is connected to the immunoglobulin Fc region, and the dimer is formed through one or more disulfide bonds in the Fc region.
  • the Fc region of the immunoglobulin comprises the Fc region of IgG1 or the Fc region of IgG2.
  • the ACE2 region is the extracellular domain of ACE2.
  • the ACE2 region contains at least 80%, at least 85%, at least 90%, at least 95%, and the sequence shown in SEQ ID NO:1. An amino acid sequence with at least 97% or at least 99% identity.
  • the ACE2 region sequence is shown in SEQ ID NO:1.
  • the method for preparing the recombinant protein of the present invention includes: (1) providing a polynucleotide molecule for encoding; (2) constructing an expression vector containing the polynucleotide molecule described in (1); (3) ) Transfecting or transforming a suitable host cell with the expression vector described in (2), and culturing in the host cell to express the protein; and (4) Purifying the protein.
  • the preparation can be carried out by techniques known to those skilled in the art.
  • the dimer of the recombinant fusion protein in the present invention is spontaneously connected by one or more disulfide bonds in the Fc region through the expressed recombinant fusion protein to form a dimer of two recombinant fusion proteins.
  • the present invention provides a polynucleotide molecule encoding a recombinant fusion protein or a recombinant protein dimer, and an expression vector for expressing the recombinant fusion protein.
  • the vectors include, but are not limited to, plasmids, viral vectors, yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), transformable artificial chromosomes (TAC), mammalian artificial chromosomes (MAC) and artificial additional chromosomes (HAEC) .
  • the present invention provides a host cell including the above-mentioned expression vector.
  • Host cells can be transformed or transfected with expression vectors.
  • Suitable host cells include E. coli, yeast and other eukaryotes.
  • E. coli, yeast or mammalian cell lines such as COS or CHO.
  • the host cell is a CHO cell.
  • Another aspect of the present invention provides a pharmaceutical composition, which comprises the above-mentioned recombinant fusion protein, the above-mentioned recombinant fusion protein dimer or the above-mentioned recombinant protein dimer, and a pharmaceutically acceptable carrier.
  • the recombinant fusion protein includes an angiotensin-converting enzyme 2 (ACE2) region, which is connected to the Fc region of immunoglobulin, and the fusion protein can bind to the spike protein of the coronavirus, thereby Blocks the binding of ACE2 to the coronavirus spike protein.
  • ACE2 angiotensin-converting enzyme 2
  • the dimer of the recombinant fusion protein includes two of the fusion protein molecules connected by one or more disulfide bonds.
  • the recombinant protein dimer includes any form of dimer formed by the ACE2 region.
  • the pharmaceutical composition may be added with a pharmaceutically acceptable carrier as required, and the carrier includes diluents, excipients, swelling agents, binding agents, wetting agents, disintegrants, absorption enhancers, Surfactants, adsorption carriers, lubricants, etc.
  • the pharmaceutical composition is administered subcutaneously, intravenously, intracutaneously, intraperitoneally, orally, intramuscularly, or intracranially.
  • administration generally refers to injection
  • injectable preparations can be prepared by publicly known methods.
  • injectable preparations can be prepared by dissolving, suspending or emulsifying the above-mentioned antibody or salt thereof in a sterile aqueous medium or oily medium conventionally used for injection.
  • aqueous medium for injection there are, for example, physiological saline, isotonic solutions containing glucose and other adjuvants, etc., which can be combined with appropriate solubilizers such as alcohols (e.g., ethanol), polyhydric alcohols (e.g., propylene glycol, polyethylene glycol) , Non-ionic surfactants [for example, polysorbate 80, hydrogenated castor oil HCO-50 (polyoxyethylene (50 mol) adduct)], etc. are used in combination.
  • the oily medium there are used, for example, sesame oil, soybean oil, etc., which can be used in combination with a solubilizer such as benzyl benzoate, benzyl alcohol, and the like. Therefore, the prepared injection is preferably filled in an appropriate ampoule.
  • the pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously using standard needles and syringes.
  • the pharmaceutical composition is administered to a subject who is infected with a coronavirus or is at risk of infection, and the coronavirus is selected from SARS-CoV, MERS-CoV or SARS-CoV-2, preferably SARS-CoV -2.
  • the pharmaceutical composition further includes a second therapeutic agent.
  • the second therapeutic agent is selected from the group consisting of anti-inflammatory drugs, antiviral drugs, other antibodies against coronavirus spike protein, vaccines against coronavirus or antibiotics.
  • the antiviral drug is selected from the group consisting of lopinavir, ribavirin, ritonavir, and remdesivir.
  • the recombinant fusion protein or recombinant protein dimer of the present invention can also be combined with non-polypeptide molecules to obtain desired properties, such as reducing degradation and/or increasing half-life, reducing toxicity, reducing immunogenicity and/or improving Biological activity.
  • non-polypeptide molecules include, but are not limited to: polymers, such as polyethylene glycol (PEG), polylysine, dextran; blood lipids; cholesterol groups (such as hormones); carbohydrates, or oligosaccharide molecules.
  • a method for preventing, treating or alleviating coronavirus infection comprising administering the above-mentioned recombinant fusion protein, the dimer of the above-mentioned recombinant fusion protein, or Recombinant protein dimer, or the above-mentioned pharmaceutical composition.
  • the coronavirus to be treated is selected from SARS-CoV, MERS-CoV or SARS-CoV-2, preferably SARS-CoV-2.
  • the present invention also provides a method for preventing, treating or alleviating coronavirus infection, the method comprising administering a protein containing the extracellular domain of ACE2 to a subject infected or suspected of being infected with a coronavirus, and the coronavirus is SARS-CoV-2
  • the amino acid sequence of the extracellular domain of ACE2 is shown in SEQ ID NO:1.
  • the protein exists as a homodimer.
  • the present invention also provides the application of the protein containing the extracellular domain of ACE2 in the preparation of drugs for preventing, treating or alleviating SARS-CoV-2 coronavirus infection, wherein the amino acid sequence of the extracellular domain of ACE2 is shown in SEQ ID NO:1.
  • the protein exists as a homodimer.
  • the present invention provides a method for preventing, treating or alleviating at least one symptom of SARS-CoV-2 infection, the method comprising adding a therapeutically effective amount of the aforementioned recombinant fusion protein, the same type of the aforementioned recombinant fusion protein
  • the dimer or pharmaceutical composition is used for subjects in need thereof.
  • the present invention provides that by administering the recombinant fusion protein or the homodimer of the recombinant fusion protein of the present invention, the severity of at least one symptom or indication of SARS-CoV-2 infection in a subject can be alleviated or reduced.
  • the at least one symptom or indication is selected from the group consisting of lung inflammation, alveolar injury, multiple ground-glass shadows or infiltration shadows in the lungs, small patches and interstitial changes outside the lungs, fever, Cough, shortness of breath, diarrhea, organ failure, septic shock, and death.
  • the present invention provides a method for reducing viral load in a subject, which comprises administering to the subject an effective amount of the aforementioned recombinant fusion protein, homodimer or pharmaceutical composition of the aforementioned recombinant fusion protein, said The recombinant fusion protein or the homodimer of the recombinant fusion protein can bind to the spike protein of SARS-CoV-2 and block the binding of SARS-CoV-2 to host cell receptors.
  • the pharmaceutical composition is administered prophylactically to a subject selected from the group consisting of immunocompromised individuals, elderly people (greater than 65 years old), medical staff, people with a history of medical problems, and People who have come into contact with people with confirmed or suspected coronavirus infections.
  • a subject selected from the group consisting of immunocompromised individuals, elderly people (greater than 65 years old), medical staff, people with a history of medical problems, and People who have come into contact with people with confirmed or suspected coronavirus infections.
  • the subject of the preventive administration is also a subject at risk of infection.
  • Another aspect of the present invention provides a method for detecting coronavirus in a sample, the method comprising: a. contacting the above-mentioned recombinant fusion protein or the homodimer of the above-mentioned recombinant fusion protein with the sample; b. determining the recombinant fusion Whether the homodimer of the protein or recombinant fusion protein specifically binds to the molecules in the sample.
  • coronavirus is selected from SARS-CoV-2.
  • the sample of the present invention is derived from serum, whole blood, sputum, oral/nasopharyngeal secretions or lotions, urine, feces, pleural effusion, cerebrospinal fluid, tissues that are infected or suspected of being infected with SARS-CoV-2 virus Specimen or non-biological samples such as water, beverages.
  • the subject of the (potential) infection can be a human, but animals suspected of carrying a coronavirus such as SARS-CoV-2 can also use the composition or pharmaceutical composition to test the presence of the coronavirus.
  • the sample can be processed first to make it more suitable for the detection method.
  • Processing refers to the processing of samples suspected of containing and/or containing coronaviruses, whereby the coronaviruses are broken down into antigenic components such as proteins, (poly) peptides or other antigenic fragments.
  • the composition or the pharmaceutical composition and the sample are in such a way that the binding molecules in the composition or the pharmaceutical composition and the coronavirus or its antigenic components that may be present in the sample form a binding complex. Contact under conditions. The formation of the binding complex indicates the presence of coronavirus in the sample, which is then detected and determined by appropriate means.
  • binding immunoassays such as radioimmunoassay (RIA), ELISA, immunofluorescence, immunohistochemistry, FACS, BIACORE, and Western blot analysis.
  • Figure 1A-1C shows the binding of ACE-2-mFc to SARS S protein or SARS-Cov-2 S protein by ELISA
  • Figure 1A shows the binding of ACE-2-mFc to the RBD domain of SARS S protein
  • Figure 1B shows ACE-2 -mFc binds to the SARS-CoV2 RBD (His tag) domain
  • Figure 1C shows the binding of ACE-2-mFc to the extracellular domain of SARS-CoV2.
  • Figure 2A shows the measurement of the binding of ACE-2-mFc to SARS S protein or SARS-Cov-2 S protein by flow cytometry.
  • the left panel of Figure 2A shows the binding of ACE-2-mFc to SARS S protein, and the right panel of Figure 2A shows ACE.
  • -2-mFc binds to SARS-Cov-2 S protein
  • Figure 2B shows the measurement of ACE-2-hFc binding to SARS S protein or SARS-Cov-2 S protein by flow cytometry.
  • the left picture of Figure 2B shows ACE-2 -hFc binds to SARS S protein.
  • the right picture of Figure 2B shows the binding of ACE-2-hFc to SARS-Cov-2 S protein.
  • Figure 3 shows the ability of ACE-2-mFc to neutralize SARS pseudovirus and SARS-Cov-2 S pseudovirus.
  • the NCP group is a pseudovirus constructed by SARS-Cov-2 envelope S protein.
  • Figure 4 is the SEC-HPLC chart of ACE-2-hFc.
  • Figures 5A-5B show the binding of ACE-2-hFc to SARS-CoV-2 S protein by ELISA.
  • Figure 5A shows the binding of ACE-2-hFc to the RBD domain of SARS-CoV-2 S protein.
  • Figure 5B shows the binding of ACE-2 to SARS-CoV-2 S protein.
  • -mFc binds to the extracellular domain of SARS-CoV2 S protein.
  • Figure 6 shows the binding of ACE-2-hFc to SARS-CoV-2 S protein measured by Biacore.
  • Figure 6A shows the binding of ACE-2-hFc to SARS-CoV-2 RBD (His tag) domain.
  • Figure 6B shows the binding of ACE-2-hFc to SARS-CoV-2 RBD (His tag) domain.
  • hFc binds to the extracellular domain of SARS-CoV-2 S protein.
  • Figure 7 shows the ability of ACE2-hFc to neutralize SARS-Cov-2 true virus.
  • Figure 8 is the experimental diagram of SARS-CoV-2 live virus challenge treatment and protection
  • Figure 8A is the body weight change curve of SARS-CoV-2 infected mice after injection of BSA and ACE2-hFc within 10 days
  • Figure 8B is the SARS-CoV infection
  • Fig. 8C shows the HE staining picture of lung slices of SARS-CoV-2 infected mice after injection of BSA and ACE2-hFc;
  • Figure 9 is the experimental diagram of the prevention and protection of SARS-CoV-2 live virus challenge.
  • Figure 9A is the body weight change curve of mice injected with BSA and ACE2-hFc within 10 days after the SARS-CoV-2 live virus is infected;
  • Figure 9B is the BSA injection
  • Figure 9C shows the lung virus infection titers of mice infected with SARS-CoV-2 live virus in mice infected with SARS-CoV-2 and ACE2-hFc.
  • Figure 9C shows mice infected with SARS-CoV-2 injected with BSA and mice injected with ACE2-hFc infected with SARS-CoV -2 HE stained picture of lung section after live virus
  • NCP coronavirus S protein ORF (see SEQ ID NO: 5 for the sequence) or SARS virus S protein DNA sequence after gene synthesis is digested with restriction DNA endonucleases HindIII and XbaI, and the same restriction endonucleases are used at the same time Plasmid vector p3XFLAG-CMV14 (Sigma, catalog number E4901), after digestion, the S protein ORF with sticky ends and plasmid vector fragments were ligated with T4 ligase to transform E.
  • CHO-3E7 cells were grown in serum-free FreeStyleTM CHO expression medium (Life Technologies, Carlsbad, California, USA). The cells were kept in an Erlenmeyer flask (Corning Inc., Acton, MA) on an orbital shaker (VWR Scientific, Chester, PA) at 37°C and 5% CO2. On the day of transfection, the DNA encoding the ACE2-Fc fusion protein of SEQ ID NO: 2 and PEI (Polysciences, Eppelheim, Germany) were mixed at a ratio of 1:2, and then added to the flask together with the cells to be transfected. About 1 ml of supernatant collected on the 5th day was used for expression level detection. The supernatant collected on day 6 was used for further purification.
  • the purified antibodies were analyzed by SDS-PAGE, Western blotting, endotoxin and SEC-HPLC, using standard procedures for molecular weight, yield and purity measurements. The results are shown in Table 1. As shown in Figure 4, the purity of the dimer of ACE2-hFc is about 95%.
  • the DNA encoded by SEQ ID NO: 3 and SEQ ID NO: 4 were used to replace the DNA encoded by SEQ ID NO: 2 to prepare another ACE2-hFc fusion protein and ACE2-mFc.
  • HEK293FT cells Inoculate HEK293FT cells (Thermo Fisher Scientific, Catalog No. R70007) in a 6-well cell culture plate at a density of 7 ⁇ 10 5 per well and 3 ml of DMEM complete medium per well. After 16 hours, 3ml of DMEM complete medium was aspirated, and 2ml of fresh DMEM complete medium was added.
  • OptiMEM serum-free medium containing PEI 100 ⁇ l of OptiMEM serum-free medium containing plasmids, and let stand at room temperature for 8 minutes, and add 200 ⁇ l of the mixture to one well of a 6-well plate to transfect HEK293FT cells. 16 hours after transfection, the medium containing the transfection mixture was replaced with 2 ml of fresh DMEM complete medium. After 6 hours, the transfected HEK293FT cells were trypsinized and centrifuged, and resuspended in pre-cooled FACS buffer (PBS buffer containing 1% FBS), and the final cell density was 1 ⁇ 10 6 cells/ml.
  • FACS buffer PBS buffer containing 1% FBS
  • ACE-2-hFc binds to SARS-Cov-2 S protein
  • ACE-2-hFc is combined with the RBD domain of SARS-CoV-2 S protein ( Figure 5A) and the extracellular region of S protein ( Figure 5A).
  • the plasmid expressing the SARS S protein and the plasmid expressing the SARS-CoV-2 S protein were transfected into HEK-293T cells.
  • the S protein of the virus is expressed on the cell surface, and ACE-2-Fc is further incubated with the cells expressing the S protein, and flow cytometry is used to detect whether ACE-2-Fc can bind to the S protein on the cell surface.
  • either ACE-2-mFc or ACE-2-hFc can bind to the SARS S protein, suggesting that the candidate molecule can correctly recognize the conformation of the target epitope.
  • either ACE-2-mFc or ACE-2-hFc can bind to SARS-Cov-2 S protein.
  • CM5 chip GE Healthcare, article number BR-1005-30
  • EDC EDC
  • the buffer solution to 2ug/ml
  • flow into the activated chip surface at 25°C at 10ul/min to react for 200s, and then flow into 1mol/L ethanolamine solution to stop the reaction for 200s.
  • HBS-EP buffer GE Healthcare, article number BR100188
  • concentrations are 1.14nM, 2.28nM, 4.56nM, 9.12nM, 18.25nM, 36.5nM, 73nM
  • Flow 30ul/min into the surface of the chip coated with SARS-CoV-2 S protein RBD or ECD detect and record the binding curve for 180s
  • flow 30ul/min into HBS-EP buffer detect and record the dissociation curve for 600s.
  • the equilibrium constant K D 4.36x10 -9 M ( Figure 6A)
  • the binding constant of ACE-2-hFc and SARS-CoV-2 S protein ECD K on 5.51x10 4 Ms -1
  • the dissociation constant K off 4.03x10 - 4 s -1
  • the equilibrium constant K D 7.32x10 -9 M (FIG. 6B).
  • the serum medium add 50 ⁇ l PEI to 500 ⁇ l OptiMEM serum-free medium at the same time, and let stand at room temperature for 5 minutes.
  • the OptiMEM serum-free medium containing PEI was mixed with 500 ⁇ l of the OptiMEM serum-free medium containing plasmids, and the mixture was allowed to stand at room temperature for 8 minutes, and 1 ml of the mixture was added to HEK293FT cells. 24 hours after transfection, the medium containing the transfection mixture was replaced with 10 ml of fresh DMEM complete medium.
  • the culture supernatant containing the pseudovirus was harvested 48 hours after transfection, filtered with a 0.45 ⁇ m pore filter, and frozen at -80°C.
  • DNA sequence of human ACE2 protein (sequence information can be found in UniProtKB, Q9BYF1).
  • the plasmid vector pLVX-Puro (Takara CatNo: 632164) was digested with the same restriction enzymes, and the ORF of human ACE2 protein was obtained after digestion.
  • DNA fragments and plasmid vector fragments with sticky ends were ligated using CloneEZ (Genscript) and transformed into competent E. coli cells to obtain plasmid pLV-Puro-ACE2.
  • HEK293FT cells Inoculate HEK293FT cells (Thermo Fisher Scientific, Catalog No. R70007) in a 6-well cell culture plate at a density of 7 ⁇ 10 5 per well and 3 ml of DMEM complete medium per well. After 16 hours, 3ml of DMEM complete medium was aspirated, and 2ml of fresh DMEM complete medium was added. After 2 hours, 5 ⁇ g of plasmid pLVX-Puro-ACE2 expressing human ACE2 protein was added to 100 ⁇ l of OptiMEM serum-free medium, while 10 ⁇ l of PEI were added to 100 ⁇ l of OptiMEM serum-free medium, and left standing at room temperature for 5 minutes.
  • OptiMEM serum-free medium containing PEI 100 ⁇ l of OptiMEM serum-free medium containing plasmids, and let stand at room temperature for 8 minutes, and add 200 ⁇ l of the mixture to one well of a 6-well plate to transfect HEK293FT cells. 16 hours after transfection, the medium containing the transfection mixture was replaced with 2 ml of fresh DMEM complete medium to obtain HEK293FT-ACE2 cells.
  • HEK293FT-ACE2 cells Inoculate HEK293FT-ACE2 cells in a 96-well flat-bottom cell culture plate at a seeding density of 5000 cells per well and 100 ⁇ l DMEM complete medium per well.
  • 25 ⁇ l of pseudovirus suspension was added to the 96-well plate for culturing HEK293FT-ACE2 cells.
  • the culture supernatant of the cells was aspirated, 200 ⁇ l of fresh DMEM complete medium was added, and the culture was continued.
  • HEK293FT-ACE2 cells Inoculate HEK293FT-ACE2 cells in a 96-well flat-bottom cell culture plate at a density of 5000 cells per well and 100 ⁇ l DMEM complete medium per well.
  • dilute ACE2-Fc with serum-free OptiMEM to a specific concentration (100ug/ml, 20ug/ml, 4ug/ml, 0.8ug/ml), mix 25 ⁇ l ACE2-Fc dilution with 25 ⁇ l pseudovirus suspension, After standing at room temperature for 1 hour, 100 ⁇ l of the suspension containing 30,000 HEK293FT-ACE2 cells was added to the antibody and virus mixture 96-well plate.
  • Figure 3 shows the results, ACE2-mFC having false virus neutralizing capacity, and neutralizing IC SARS-CoV-2 of 50 (10.2nM) ratio of SARS-CoV and the IC 50 (107.4nM) is about 10 times lower , Suggesting that ACE-2-mFC is more effective for SARS-CoV-2.
  • Vero-E6 cells Inoculate Vero-E6 cells in a 24-well flat-bottom cell culture plate with a seeding density of 160,000 cells per well and 1ml DMEM complete medium per well.
  • dilute ACE2-hFc with PBS to a specific concentration (100ul/ml, 50ug/ml, 16.67ug/ml, 5.56ug/ml, 1.85ug/ml, 0.62ug/ml, 0.21ug/ml)
  • 50 ⁇ l ACE2-hFc dilution with 50ul SARS-CoV-2 live virus suspension containing 150FFU (concentrated forming unit) (provided by the P3 laboratory of Guangzhou Medical University and commissioned to perform the following experiments).
  • Infection inhibition rate 1-(average number of positive spots in the no antibody group-number of positive spots in the antibody test group)/average number of positive spots in the no antibody group x 100%.
  • the results in Figure 7 show that ACE2-hFc has the ability to neutralize live viruses, and the IC 50 for neutralizing live SARS-CoV-2 viruses is 4.1 nM.
  • mice were inoculated intranasally with adenovirus Ad5-hACE2 (source can be found in Cell.2020Aug 6; 182(3):734-743.e5.) overexpressing human ACE2 protein in the lungs.
  • Ad5-hACE2 source can be found in Cell.2020Aug 6; 182(3):734-743.e5.
  • ACE2-hFc or BSA was injected intraperitoneally on the second day after virus inoculation, and the injection dose was 50 mg/kg.
  • mice were weighed every day to the 10th day after inoculation.
  • Fig. 8A show that, compared with injection of BSA, injection of ACE2-hFc can significantly alleviate the weight loss of mice infected with SARS-CoV-2.
  • Fig. 8B show that the live SARS-CoV-2 virus infection titer in the lungs of mice injected with ACE2-hFc was significantly reduced.
  • Fig. 8C showed that the lungs of mice injected with ACE2-hFc did not show pulmonary fibrosis and immune cell infiltration caused by virus infection.
  • mice were inoculated intranasally with adenovirus Ad5-hACE2 to overexpress human ACE2 protein in the lungs.
  • Ad5-hACE2 to overexpress human ACE2 protein in the lungs.
  • ACE2-hFc or BSA was injected intraperitoneally at a dose of 50 mg/kg.
  • 10 5 TCID units of SARS-CoV-2 live virus were inoculated by intranasal drip (provided by P3 Laboratory of Guangzhou Medical University) .
  • mice were weighed every day to the 10th day after SARS-CoV-2 live virus infection.
  • Fig. 9A shows Compared with BSA injection, ACE2-hFc injection can significantly alleviate the weight loss of mice infected with SARS-CoV-2.
  • Fig. 9A shows Compared with BSA injection, ACE2-hFc injection can significantly alleviate the weight loss of mice infected with SARS-CoV-2.
  • FIG. 9B show that the SARS-CoV-2 live virus infection titer in the lungs of mice injected with ACE2-hFc was significantly reduced.
  • Fig. 9C showed that the lungs of mice injected with ACE2-hFc did not show pulmonary fibrosis and immune cell infiltration caused by virus infection.
  • SEQ ID NO: 5 DNA sequence of NCP coronavirus S protein ORF

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une méthode de traitement de coronavirus à l'aide d'une protéine de fusion ACE-2-Fc, se rapportant au domaine du traitement de virus. L'invention concerne une protéine de fusion recombinée, la protéine comprenant une région d'enzyme de conversion de l'angiotensine 2 (ACE2) reliée à une région Fc d'immunoglobuline, et la protéine de fusion pouvant se lier à une protéine de spicule de coronavirus, bloquant ainsi la liaison d'ACE2 à la protéine de spicule de coronavirus. L'invention concerne également une méthode de prévention, de traitement ou de soulagement d'infections à coronavirus. La méthode comprend l'administration d'une protéine comprenant un domaine extracellulaire d'ACE2 à un sujet infecté ou suspecté d'être infecté par un coronavirus, le coronavirus étant le SARS-Cov-2, et le domaine extracellulaire d'ACE2 comprenant une séquence d'acides aminés représentée par la SEQ ID NO : 1, la protéine se présentant sous la forme d'un dimère.
PCT/CN2021/078270 2020-02-29 2021-02-26 Méthode de traitement de coronavirus à l'aide d'une protéine de fusion ace-2-fc Ceased WO2021170113A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010132178.7 2020-02-29
CN202010132178 2020-02-29

Publications (1)

Publication Number Publication Date
WO2021170113A1 true WO2021170113A1 (fr) 2021-09-02

Family

ID=77490725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/078270 Ceased WO2021170113A1 (fr) 2020-02-29 2021-02-26 Méthode de traitement de coronavirus à l'aide d'une protéine de fusion ace-2-fc

Country Status (1)

Country Link
WO (1) WO2021170113A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112375149A (zh) * 2020-10-30 2021-02-19 沣潮医药科技（上海）有限公司 Ace2免疫融合蛋白及其应用
WO2021234160A3 (fr) * 2020-05-22 2022-01-13 Formycon Ag Protéines de fusion d'ace2 et leurs utilisations
WO2022090469A2 (fr) 2020-10-29 2022-05-05 Formycon Ag Protéines de fusion ace2 et leurs utilisations
CN114740199A (zh) * 2022-03-18 2022-07-12 北京安奇生物医药科技有限公司 一种SARS-CoV-2中和抗体试剂盒及其应用
WO2022184854A2 (fr) 2021-03-03 2022-09-09 Formycon Ag Formulations de protéines de fusion ace2 fc
WO2023006935A3 (fr) * 2021-07-30 2023-03-30 Formycon Ag Protéines de fusion ace2 et leurs utilisations
WO2023094571A1 (fr) 2021-11-25 2023-06-01 Formycon Ag Stabilisation de protéines de fusion ace2
WO2023232095A1 (fr) * 2022-05-31 2023-12-07 康码（上海）生物科技有限公司 Formulation de pulvérisation orale à base d'agent de blocage de virus, et son utilisation
WO2023246853A1 (fr) * 2022-06-24 2023-12-28 广东菲鹏制药股份有限公司 Protéine de liaison multivalente humanisée anti-sars-cov-2 et son utilisation
EP4331571A1 (fr) 2022-09-02 2024-03-06 Formycon AG Formulations de protéines de fusion ace2-igm
WO2024183704A1 (fr) * 2023-03-04 2024-09-12 四川三叶草生物制药有限公司 Nouveau spray nasal protecteur contre le coronavirus, sa préparation et son utilisation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028497A2 (fr) * 2003-09-15 2005-03-31 The Brigham And Women's Hospital Inc. Peptides se liant a des recepteurs derives de proteines sars s
WO2006122819A1 (fr) * 2005-05-19 2006-11-23 Imba-Institut Für Molekulare Biotechnologie Gmbh Utilisation d'inhibiteurs de ras
WO2006136084A1 (fr) * 2005-06-20 2006-12-28 Chinese Academy Of Medical Sciences, Institute Of Basic Medical Sciences Proteines de fusion de proteines structurales recombinantes du coronavirus sars, leur production et leurs utilisations
CN107569679A (zh) * 2017-09-06 2018-01-12 首都医科大学附属北京同仁医院 Ace2在调控棕色脂肪组织活性中的应用
WO2018140456A1 (fr) * 2017-01-24 2018-08-02 Northwestern University Variants actifs de bas poids moléculaire de l'enzyme de conversion de l'angiotensine ii (eca ii)
CN110114369A (zh) * 2016-10-17 2019-08-09 威隆股份公司 修饰的抗体恒定区

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028497A2 (fr) * 2003-09-15 2005-03-31 The Brigham And Women's Hospital Inc. Peptides se liant a des recepteurs derives de proteines sars s
WO2006122819A1 (fr) * 2005-05-19 2006-11-23 Imba-Institut Für Molekulare Biotechnologie Gmbh Utilisation d'inhibiteurs de ras
WO2006136084A1 (fr) * 2005-06-20 2006-12-28 Chinese Academy Of Medical Sciences, Institute Of Basic Medical Sciences Proteines de fusion de proteines structurales recombinantes du coronavirus sars, leur production et leurs utilisations
CN110114369A (zh) * 2016-10-17 2019-08-09 威隆股份公司 修饰的抗体恒定区
WO2018140456A1 (fr) * 2017-01-24 2018-08-02 Northwestern University Variants actifs de bas poids moléculaire de l'enzyme de conversion de l'angiotensine ii (eca ii)
CN107569679A (zh) * 2017-09-06 2018-01-12 首都医科大学附属北京同仁医院 Ace2在调控棕色脂肪组织活性中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANGHAI LEI, WENYAN FU, KEWEN QIAN, TIAN LI, SHENG ZHANG, MIN DING, SHI HU: "Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig", BIORXIV, 3 February 2020 (2020-02-03), XP055745522, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.02.01.929976v2.full.pdf> DOI: 10.1101/2020.02.01.929976 *
PAN LIU, WYSOCKI JAN, SOUMA TOMOKAZU, YE MINGHAO, RAMIREZ VERONICA, ZHOU BISHENG, WILSBACHER LISA D., QUAGGIN SUSAN E., BATLLE DAN: "Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation", KIDNEY INTERNATIONAL, NATURE PUBLISHING GROUP, LONDON, GB, vol. 94, no. 1, 1 July 2018 (2018-07-01), GB, pages 114 - 125, XP055745670, ISSN: 0085-2538, DOI: 10.1016/j.kint.2018.01.029 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021234160A3 (fr) * 2020-05-22 2022-01-13 Formycon Ag Protéines de fusion d'ace2 et leurs utilisations
WO2022090469A2 (fr) 2020-10-29 2022-05-05 Formycon Ag Protéines de fusion ace2 et leurs utilisations
WO2022090469A3 (fr) * 2020-10-29 2022-07-21 Formycon Ag Protéines de fusion ace2 et leurs utilisations
CN112375149A (zh) * 2020-10-30 2021-02-19 沣潮医药科技（上海）有限公司 Ace2免疫融合蛋白及其应用
WO2022184854A2 (fr) 2021-03-03 2022-09-09 Formycon Ag Formulations de protéines de fusion ace2 fc
WO2023006935A3 (fr) * 2021-07-30 2023-03-30 Formycon Ag Protéines de fusion ace2 et leurs utilisations
WO2023094571A1 (fr) 2021-11-25 2023-06-01 Formycon Ag Stabilisation de protéines de fusion ace2
CN114740199A (zh) * 2022-03-18 2022-07-12 北京安奇生物医药科技有限公司 一种SARS-CoV-2中和抗体试剂盒及其应用
WO2023232095A1 (fr) * 2022-05-31 2023-12-07 康码（上海）生物科技有限公司 Formulation de pulvérisation orale à base d'agent de blocage de virus, et son utilisation
WO2023246853A1 (fr) * 2022-06-24 2023-12-28 广东菲鹏制药股份有限公司 Protéine de liaison multivalente humanisée anti-sars-cov-2 et son utilisation
EP4331571A1 (fr) 2022-09-02 2024-03-06 Formycon AG Formulations de protéines de fusion ace2-igm
WO2024183704A1 (fr) * 2023-03-04 2024-09-12 四川三叶草生物制药有限公司 Nouveau spray nasal protecteur contre le coronavirus, sa préparation et son utilisation

Similar Documents

Publication Publication Date Title
WO2021170113A1 (fr) Méthode de traitement de coronavirus à l&#39;aide d&#39;une protéine de fusion ace-2-fc
US20240067706A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
JP2020532953A (ja) コンフォメーションが安定化されたｒｓｖ融合前ｆタンパク質
US8431118B2 (en) Anti-herpes simplex virus antibodies and methods of use thereof
JP2024502046A (ja) Ｃｏｖｉｄ－１９に対する中和モノクローナル抗体
US20230174611A1 (en) Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor
EP4130047A1 (fr) Ace2 soluble et protéine de fusion et leurs utilisations
CN118772250B (zh) 一种rsv f蛋白突变体及其制法与应用
WO2025129864A1 (fr) Mutant amélioré de la protéine f de fusion du virus respiratoire syncytial et son utilisation
JP2023534923A (ja) ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子
WO2023008553A1 (fr) Anticorps de poulet contre un variant de coronavirus
TWI454279B (zh) 抗單純皰疹病毒抗體及其使用方法
CN116209672A (zh) Sars-cov-2抑制剂
KR102765237B1 (ko) Rsv의 f 단백질-항체 복합체 및 이를 포함하는 조성물
AU2022346446A1 (en) Multivalent polypeptide constructs capable of binding viral spike proteins and methods of using the same
CN112574298B (zh) 一种抗西尼罗河病毒的人源中和性抗体
CN112574297B (zh) 抗神经氨酸酶的单克隆抗体及其应用
WO2021207207A2 (fr) Leurres protéiques de novo de l&#39;enzyme 2 de conversion de l&#39;angiotensine (ace2)
WO2024229151A2 (fr) Molécules de liaison à un coronavirus multimères et leurs utilisations
RU2837537C1 (ru) Растворимый апф2, его слитый белок и способы их применения
US20230265144A1 (en) Interleukin 29 mutant protein
EP4653469A1 (fr) Protéine de fusion de ge et gi du virus varicelle-zona et utilisation
WO2024182370A1 (fr) Protéines de fusion ace2-igm-fc et leurs utilisations
WO2023131262A1 (fr) Protéine de liaison à l&#39;antigène spécifiquement liée au sars-cov-2
WO2023143176A1 (fr) Anticorps à large spectre du virus sars-cov-2 et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21760286

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21760286

Country of ref document: EP

Kind code of ref document: A1